ARTICLE | Company News
BTG gets Genentech peptide technology
September 4, 2001 7:00 AM UTC
Genentech (DNA) granted BTG (LSE:BGC) exclusive rights to develop and market its Atrial Natriuretic Factor (ANF) peptide technology. BGC said ANF has been shown to have therapeutic potential in treati...